Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SKB264 |
Synonyms | |
Therapy Description |
SKB264 is an antibody-drug conjugate (ADC) composed of a monoclonal antibody that targets trophoblast cell surface protein 2 (TROP2) linked to a topoisomerase I inhibitor, which delivers the drug to TROP2-expressing tumor cells, potentially resulting in antitumor activity (Cancer Res (2024) 84 (7_Supplement): CT038). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SKB264 | SKB 264|SKB-264|ADC SKB264|MK-2870|MK 2870|MK2870|Sacituzumab tirumotecan | TROP2 Antibody 13 | SKB264 is an antibody-drug conjugate (ADC) composed of a monoclonal antibody that targets trophoblast cell surface protein 2 (TROP2) linked to a topoisomerase I inhibitor, which delivers the drug to TROP2-expressing tumor cells, potentially resulting in antitumor activity (Cancer Res (2024) 84 (7_Supplement): CT038). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04152499 | Phase Ib/II | SKB264 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264) | Recruiting | USA | TUR | CAN | 2 |
NCT06459180 | Phase III | Gemcitabine Irinotecan Tisotumab vedotin-tftv Pemetrexed Disodium Vinorelbine Topotecan SKB264 | A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) | Recruiting | USA | SWE | POL | NOR | NLD | ITA | ISR | IRL | GRC | FRA | FIN | ESP | DNK | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 7 |
NCT06305754 | Phase III | Carboplatin + Pemetrexed Disodium SKB264 | Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) | Recruiting | USA | TUR | SWE | POL | ITA | FRA | ESP | CAN | ARG | 8 |
NCT06074588 | Phase III | Docetaxel SKB264 Pemetrexed Disodium | Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) | Recruiting | USA | TUR | POL | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | AUS | 11 |
NCT06428409 | Phase Ib/II | Fluorouracil + Leucovorin + SKB264 SKB264 | A Clinical Study of MK-2870 Alone or With Chemotherapy to Treat Gastrointestinal Cancers (MK-9999-02A) | Recruiting | USA | ITA | GBR | ESP | CHE | CAN | AUS | 5 |
NCT06132958 | Phase III | Paclitaxel Doxorubicin SKB264 | MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) | Recruiting | USA | SWE | POL | NOR | NLD | ITA | ISR | IRL | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 8 |
NCT06356311 | Phase III | Trifluridine-tipiracil hydrochloride Irinotecan Paclitaxel Docetaxel SKB264 | A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) | Recruiting | USA | POL | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CAN | BRA | BEL | 9 |